Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1: 10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies …

Background In a recent study, autoantibodies neutralizing type I interferons (IFNs) were
present in at least 10% of cases of critical COVID-19 pneumonia. These autoantibodies …

Recent studies reported the presence of pre-existing autoantibodies (auto-Abs) neutralizing
type I interferons (IFNs) in at least 15% of patients with critical COVID-19 pneumonia. In one …

Purpose Autoantibodies (aAbs) to type I interferons (IFNs) have been found in less than 1%
of individuals under the age of 60 in the general population, with the prevalence increasing …

INTRODUCTION Interindividual clinical variability is vast in humans infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to …

We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19
pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients …

Neutralizing autoantibodies against type I interferons (IFNs) have been found in some
patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe …

A significant number of COVID‐19 patients were shown to have neutralizing antibodies
(NAB) against IFN; however, NAB specificity, fluctuation over time, associations with …

Objectives Impairment of type I interferon (IFN‐I) immunity has been reported in critically ill
COVID‐19 patients. This defect can be explained in a subset of patients by the presence of …